Tag: addisons disease
Apr 28, 2011 01:00 EDT The Swedish specialty pharma company, DuoCort Pharma and UK-based global provider Clinigen, announce that they have concluded an agreement whereby Clinigen will manage a Named Patient Programme for Plenadren, a novel treatment for Addison´s disease. The product has orphan status in Europe and the USA and is currently in the European Union (EU) registration process for marketing authorisation.
Jun 29, 2009 00:30 EDT Helsingborg June 29th 2009- DuoCort publishes data from its Phase I study for the rare and life threatening disease adrenal insufficiency. The release profile of DuoCort’s new form of treatment with once-a-day hydrocortisone dosing resembles the physiological secretion pattern. The data is published today in the European Journal of Endocrinology, a leading scientific journal for endocrinology.
Jun 12, 2009 00:00 EDT Helsingborg/ Washington DC June 12th 2009- DuoCort gained promising data from its Phase II/III study for the rare and life threatening disease adrenal insufficiency. DuoCort’s new form of physiological treatment with once daily dosing show improved cardiovascular measures compared to standard hydrocortisone given thrice daily. The company presents the data at the ENDO congress in Washington DC.
Mar 15, 2011 01:30 EDT DuoCort’s new form of physiological treatment for the rare and life threatening disease adrenal insufficiency, also called Addison´s disease, was recently granted a registered Community Trademark within the EU. The trademark is PLENADREN. The product, which has orphan status in Europe and the USA, is currently in the European Union (EU) registration process for marketing authorisation.
